Laws and Labels: A Regulatory View of Biosimilars
Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.
You may also like:
Pain management is an area of concern for many healthcare professionals, and not just because it’s so prevalent in the national news cycle. In her article “To tre...
Because of the concern about prescription opioid abuse and the growing numbers of dependent opioid users switching to heroin, it is of interest to ascertain the rate and incidence of such transition. Accord...
NCPDP, the standards development organization focused on the pharmacy sector, just wrapped up its annual business and technology conference, which immediately followed its quarterly technical ...
Stay in the Know
Sign up to start receiving notifications via email of our upcoming webinars!